Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 19;7(11):ofaa500.
doi: 10.1093/ofid/ofaa500. eCollection 2020 Nov.

Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19

Sarah M Lofgren  1 , Melanie R Nicol  1 , Ananta S Bangdiwala  1 , Katelyn A Pastick  1 , Elizabeth C Okafor  1 , Caleb P Skipper  1 , Matthew F Pullen  1 , Nicole W Engen  1 , Mahsa Abassi  1 , Darlisha A Williams  1 , Alanna A Nascene  1 , Margaret L Axelrod  2 , Sylvain A Lother  3 , Lauren J MacKenzie  3 , Glen Drobot  3 , Nicole Marten  4 , Matthew P Cheng  5   6 , Ryan Zarychanski  3   4 , Ilan S Schwartz  7 , Michael Silverman  8 , Zain Chagla  9 , Lauren E Kelly  4 , Emily G McDonald  5   6 , Todd C Lee  5   6 , Kathy H Hullsiek  1 , David R Boulware  1 , Radha Rajasingham  1
Affiliations

Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19

Sarah M Lofgren et al. Open Forum Infect Dis. .

Abstract

Background: Use of hydroxychloroquine in hospitalized patients with coronavirus disease 2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from 3 outpatient randomized clinical trials.

Methods: We conducted 3 randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, postexposure prophylaxis, and early treatment for COVID-19 using an internet-based design. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings.

Results: We enrolled 2795 participants. The median age of research participants (interquartile range) was 40 (34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2544 (91%) participants reported side effect data, and 748 (29%) reported at least 1 medication side effect. Side effects were reported in 40% with once-daily, 36% with twice-weekly, 31% with once-weekly hydroxychloroquine, compared with 19% with placebo. The most common side effects were upset stomach or nausea (25% with once-daily, 19% with twice-weekly, and 18% with once-weekly hydroxychloroquine, vs 11% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for once-daily, 17% twice-weekly, and 13% once-weekly hydroxychloroquine, vs 7% for placebo). Two individuals were hospitalized for atrial arrhythmias, 1 on placebo and 1 on twice-weekly hydroxychloroquine. No sudden deaths occurred.

Conclusions: Data from 3 outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials, in cohorts of healthy outpatients, can safely investigate whether hydroxychloroquine is efficacious for COVID-19.

Clinicaltrialsgov identifier: NCT04308668 for postexposure prophylaxis and early treatment trials; NCT04328467 for pre-exposure prophylaxis trial.

Keywords: COVID-19; SARS-Cov2; hydroxychloroquine; safety; side effects.

PubMed Disclaimer

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2:69. - PMC - PubMed
    1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:732–9. - PMC - PubMed
    1. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020; 383:517–25. - PMC - PubMed
    1. Pastick KA, Okafor EC, Wang F, et al. Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020; 7:ofaa130. - PMC - PubMed
    1. RECOVERY Trial. Statement from the chief investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) trial on hydroxychloroquine, 5 June 2020. Available at: https://www.recoverytrial.net/results. Accessed 5 June 2020.

Associated data